0415SP |
Chlorophacinone (Qualitative), Serum/Plasma |
1030B |
Carisoprodol and Metabolite, Blood |
1030FL |
Carisoprodol and Metabolite, Fluid |
1030SP |
Carisoprodol and Metabolite, Serum/Plasma |
1030U |
Carisoprodol and Metabolite, Urine |
1180B |
Chlorothiazide, Blood |
1180SP |
Chlorothiazide, Serum/Plasma |
1255B |
Chlorzoxazone, Blood |
1255SP |
Chlorzoxazone, Serum/Plasma |
1405B |
Cyclobenzaprine, Blood |
1405FL |
Cyclobenzaprine, Fluid |
1405SP |
Cyclobenzaprine, Serum/Plasma |
1405TI |
Cyclobenzaprine, Tissue |
1405U |
Cyclobenzaprine, Urine |
4207B |
Canrenone (Spironolactone metabolite), Blood |
4207SP |
Canrenone (Spironolactone metabolite), Serum/Plasma |
9129B |
Carisoprodol and Metabolite Screen, Blood |
9129FL |
Carisoprodol and Metabolite Screen, Fluid |
9129SP |
Carisoprodol and Metabolite Screen, Serum/Plasma |
9145UC |
Comprehensive Drug Screen, Umbilical Cord Tissue Overview: Detection of in utero exposure to drugs of abuse consistent with maternal use during the second and third trimesters of pregnancy; Newborn (neonatal) toxicology |